Inflammatory bowel disease (IBD), comprising Crohn's disease (CD) and ulcerative colitis
(UC), is a heterogeneous state of chronic intestinal inflammation with no exact known cause …

Since the late 1990s, tumor necrosis factor alpha (TNF-α) inhibitors (anti-TNFs) have
revolutionized the therapy of immune-mediated inflammatory diseases (IMIDs) affecting the …

(1) Background: Evidence on the outcomes of ustekinumab treatment in real-world Crohn's
disease (CD) patients is needed. Our aim was to evaluate the effectiveness and safety of …

Surgery for Crohn's disease (CD) is not curative, as postoperative recurrence (POR) after
ileocolonic resection is the rule in the absence of prophylactic treatment. In the present …

Inflammatory bowel diseases (IBDs) are chronic and disabling conditions that, uncontrolled,
lead to irreversible bowel damage and associated comorbidities. Despite the new era of …

Background Rates of enrolment in clinical trials in inflammatory bowel disease [IBD] have
decreased dramatically in recent years. This has led to delays, increased costs and failures …

Tumor necrosis factor-α (TNF-α) antagonists, the first biologics approved for treating patients
with inflammatory bowel disease (IBD), are effective for the induction and maintenance of …

Background Mirikizumab, a p19-directed interleukin-23 monoclonal antibody, is efficacious
in inducing clinical remission at week 12 (W12) and maintaining clinical remission at W52 in …

Background Chronic spontaneous urticaria (CSU) is a chronic inflammatory disease
characterized by recurrent pruritic wheals (hives) and/or angioedema. Patients with CSU …

Background Anti-TNF medications are the first-line treatment for Crohn's Disease (CD),
despite the fact that a significant portion of the population continues to be ineffectively …